Trends in insulin use, glycemic control explored

Trends in insulin use, glycemic control explored

(HealthDay)—Since 1988, the proportion of patients with diabetes currently on any insulin has remained stable, according to research published online Dec. 30 in Diabetes Care.

Elizabeth Selvin, Ph.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues examined national trends in glycemic control by and oral diabetes medication use. Data were included for 4,947 adult participants with diagnosed diabetes in the National Health and Nutrition Examination Survey for the 1988 to 1994 and 1999 to 2012 cycles.

The researchers found that the proportion of patients with diabetes currently on insulin was relatively stable (29.1 percent in 2005 to 2012; 30.3 percent in 1988 to 1994; and 24.8 percent in 1999 to 2004). Diabetes duration was a strong independent determinant of insulin use. During the study period, the duration of diabetes increased significantly for those on any insulin (12.7 to 17.3 years; P < 0.001), compared with diabetes duration for those on oral medication only (7.0 to 8.5 years; P = 0.36). Among patients with any insulin use, 31.4 percent had an hemoglobin A1c (HbA1c) <7 percent, while 61.7 percent had HbA1c <8 percent in 2005 to 2012.

"Our results suggest improvements are needed in patient and professional education on insulin use, new insulin formulations and delivery technology, and/or systems of care to improve in patients receiving insulin," the authors write.

More information: Full Text (subscription or payment may be required)

Journal information: Diabetes Care

Copyright © 2016 HealthDay. All rights reserved.

Citation: Trends in insulin use, glycemic control explored (2016, January 8) retrieved 1 May 2024 from https://medicalxpress.com/news/2016-01-trends-insulin-glycemic-explored.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Basal insulin peglispro beats glargine for glycemic control

0 shares

Feedback to editors